SEC Form 4 · accession 0001104659-26-082009
Cellectar Biosciences, Inc. · CLRB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
A later amendment supersedes this filing — read the amendment. The figures below are kept as originally reported (version chain, not an overwrite).
Reporting owner
Stefan Loren
Other
Period of report
Jul 8, 2026
Accepted (ET)
Jul 8, 2026 · 9:00 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001279704
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock option (right to buy)F1 | $2.68 | Jul 8, 2026 | A | 15,000 | A | — | Jul 8, 2036 | Common stock | 15,000 | 15,000 | D |
Explanation of responses
- F1This option shall vest in full on July 8, 2027, subject to the reporting person's continued service through the applicable vesting date.